- |||||||||| Adstiladrin (nadofaragene firadenovec-vncg) / Ferring, Keytruda (pembrolizumab) / Merck (MSD), Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Review, Journal: Recent Advances in Drug Delivery Strategies for High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: A Brief Review from 2018 to 2024. (Pubmed Central) - Sep 29, 2024 This review focuses on high-risk BCG-unresponsive NMIBC therapies that have been or are currently being investigated in clinical trials, offering a broad overview of the delivery system designs and up-to-date clinical outcomes that have been reported as of July 2024. It aims to inform the development of future drug delivery systems for second-line therapies in high-risk BCG-unresponsive NMIBC.
- |||||||||| Darzalex (daratumumab) / J&J
Journal: The Perspective of Romanian Patients on Continuous Therapy for Multiple Myeloma. (Pubmed Central) - Sep 29, 2024 Although continuous therapy is associated with a high financial burden and a negative impact on both professional and personal life, the frequent visits to the hospital appear to be reassuring. Moreover, the patients would not opt for treatment discontinuation and felt safer when monitored frequently.
- |||||||||| Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Clinical, Journal, Real-world evidence, Real-world: Real-World Data with CDK4/6 Inhibitors-A Single Center Experience from Croatia. (Pubmed Central) - Sep 29, 2024 Our study provides the RWD with the use of CDK4/6 inhibitors in the treatment of metastatic HR+/HER2- breast cancer. To our best knowledge, there are limited RWD regarding CDK 4/6 inhibitors use in western Balkan; thus, our study provides valuable data from everyday clinical practice for this region of Europe, bridging the gap between randomized clinical trials and clinical reality in western Balkan.
- |||||||||| Retrospective data, Journal, Checkpoint inhibition, PD(L)-1 Biomarker, IO biomarker, Metastases: The Evaluation of Immune Checkpoint Inhibitors and BRAF/MEK Inhibitors in Different Therapy Lines for Metastatic Melanoma: A Retrospective Study. (Pubmed Central) - Sep 29, 2024
We retrospectively evaluated 22 melanoma patients treated with nivo/ipi therapy and 13 patients treated with encorafenib plus binimetinib (enco/bini) between November 2018 and July 2023...In addition to efficacy, the incidence of grade 3 or greater AEs was comparable in the first-line and second-line or beyond cohorts. Although our present data are based on a small number of cases, they suggest that nivo/ipi should be administered as the first-line therapy for the treatment of BRAFV600-mutant metastatic melanoma, rather than enco/bini, aligning with findings from previous clinical trials.
- |||||||||| Herceptin (trastuzumab) / Roche, Rituxan (rituximab) / Roche
Review, Journal: Revolutionizing Cancer Treatment: Recent Advances in Immunotherapy. (Pubmed Central) - Sep 29, 2024 Future research should address these obstacles through emerging technologies, such as next-generation antibodies, Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-based gene editing, and AI-driven drug discovery. By integrating these novel approaches, cancer immunotherapy holds the promise of offering more durable, less toxic, and highly personalized treatment options, ultimately improving patient outcomes and survival rates.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Journal, PD(L)-1 Biomarker, IO biomarker: Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial. (Pubmed Central) - Sep 28, 2024 The significant overall survival benefit of neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone coupled with a manageable safety profile support the use of perioperative pembrolizumab in patients with resectable, early-stage NSCLC. The 7-year analysis of adjuvant therapy with pembrolizumab demonstrated a sustained improvement in the long-term RFS, DMFS and PRFS2 compared with placebo in patients with resected stage III melanoma.
- |||||||||| Xalkori (crizotinib) / Pfizer
Journal: Synergistic effects of combined BET and FAK inhibition against Vestibular Schwannomas in NF2-related Schwannomatosis. (Pubmed Central) - Sep 28, 2024 We have previously identified that BET inhibition can selectively reduce growth of the NF2-null schwannoma and Schwann cells in vitro and tumorigenesis in vivo and, separately, reported that inhibition of Focal Adhesion Kinase 1 (FAK1) via crizotinib has antiproliferative effects in NF2-null Schwann cells...Further, we identify the mechanism of action through the downregulation of FAK1 transcription by BET inhibition, which potentiates inhibition of FAK by 100-fold. Our findings suggest that combined targeting of BET and FAK1 may offer a potential therapeutic option for the treatment of NF2-related schwannomas.
- |||||||||| Yidafan (ivonescimab) / Akesobio, Summit Therapeutics
Review, Journal, PD(L)-1 Biomarker, IO biomarker: Ivonescimab: First Approval. (Pubmed Central) - Sep 28, 2024 Clinical studies of ivonescimab are underway in multiple countries worldwide. This article summarizes the milestones in the development of ivonescimab leading to this first approval for EGFR-mutated locally advanced or metastatic non-squamous NSCLC who have progressed after TKI therapy.
- |||||||||| Rituxan (rituximab) / Roche
Spontaneous Remission of Advanced Follicular Lymphoma Following SARSCOV-2 Infection: A Case Report (e-Poster Area) - Sep 27, 2024 - Abstract #EANM2024EANM_2736; The response/remission of lymphomas induced by SARSCOV-2 infection, although it is rare, some cases have been described. We consider it important to exhaustively assess the patient's clinical history and be aware of this possibility, in order to carry out a correct evaluation of the patient.
- |||||||||| Polivy (polatuzumab vedotin-piiq) / Roche
New-onset pancreatic involvement on a follow-up 18FDG PET-CT in a patient with non-Hodgkin's lymphoma. (e-Poster Area) - Sep 27, 2024 - Abstract #EANM2024EANM_2599; Receives 1st line treatment according to the R-miniCHOP scheme for 6 cycles between April and July 2023. The pancreatic hypermetabolic focis found in control 18FDG PET-CT in cancer patients, although rare, seem to have a high rate of malignancy, so their directed study is essential to characterize them, although the research carried out for this purpose until the date is scarce.
- |||||||||| Rituxan (rituximab) / Roche
A Case Report: Primary Renal Lymphoma Presenting with a Pathological Femur Fracture (e-Poster Area) - Sep 27, 2024 - Abstract #EANM2024EANM_2541; The whole-body scanning capability of F18 FDG PET-CT is critically important for detecting the disease's primary focus, identifying extranodal lesions, and monitoring the treatment process. In the presented case, in addition to conventional imaging methods, F18 FDG PET-CT detected not only the renal mass but also lymph node involvement in abdominal and pelvic areas.
- |||||||||| Rituxan (rituximab) / Roche
Development of a click radio-iodination labeling method using the[125I]Iodo-azide/ADIBO pair (e-Poster Area) - Sep 27, 2024 - Abstract #EANM2024EANM_2476; In the presented case, in addition to conventional imaging methods, F18 FDG PET-CT detected not only the renal mass but also lymph node involvement in abdominal and pelvic areas. High labeling rates were achieved through successful click radio-iodination of ADIBO-rituximab antibody using the newly developed [125I]Iodoazide.
- |||||||||| Imfinzi (durvalumab) / AstraZeneca
Generalizing Deep Learning Denoising for Novel PET Radiotracers to improve image quality (e-Poster Area) - Sep 27, 2024 - Abstract #EANM2024EANM_2365; In silico denoising by our deep-learning-based model seems to at least partially generalize to 89Zr-labelled radiotracers as shown by this study on [89Zr]Zr-DFO-durvalumab. Strategies for post-hoc enhancement of PET-scans may help to harmonize scan quality, which facilitates pooled analyses of multi-center studies using less commonly used radiotracers.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS
18F-FDG PET/CT imaging predictions of immunotherapy-related adverse effects - single Center experience (e-Poster Area) - Sep 27, 2024 - Abstract #EANM2024EANM_1851; FDG PET-CT was also highly predictive of irAEs among 29 pts received IT alone and accurately identified pts who has severe irAEs and need to change therapy management. So, we concluded that early detection of irAEs is essential to aid management of patients and to reduce associated morbidity.
|